10-Q: Theravance Biopharma Reports Q1 2025 Financial Results, Cites Progress in Key Programs

Theravance Biopharma announces its Q1 2025 financial results, highlighting revenue growth from YUPELRI and advancements in the ampreloxetine clinical program.

Summary

• Theravance Biopharma reported a net loss of $13.579 million for the three months ended March 31, 2025, compared to a net loss of $11.664 million for the same period in 2024.
• Revenue from the Viatris collaboration agreement was $15.388 million, a 6% increase from $14.503 million in the prior year, driven by increased YUPELRI net sales.
• Research and development expenses increased to $11.452 million from $8.968 million, primarily due to the progression of the ampreloxetine Phase 3 clinical study.
• Selling, general, and administrative expenses rose to $18.370 million from $16.742 million, driven by pre-launch medical affairs and commercialization expenses for ampreloxetine.
• The company received a $50 million milestone payment from Royalty Pharma related to 2024 TRELEGY global net sales.
• As of March 31, 2025, Theravance Biopharma had $130.9 million in cash, cash equivalents, and marketable securities.
• The company expects its cash, cash equivalents, and marketable securities will be sufficient to fund its operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's revenue growth and a milestone payment, the increased net loss and R&D expenses temper the positive aspects. The company's future depends on the success of its clinical programs and commercialization efforts.

Positives

• Revenue from the Viatris collaboration increased by 6% due to higher YUPELRI net sales.
• The company received a $50 million milestone payment from Royalty Pharma.
• The Phase 3 study of YUPELRI in China was positive, and a registrational filing has been completed.
• The FDA granted Orphan Drug Designation to ampreloxetine for the treatment of symptomatic nOH in patients with MSA.
• The company expects its cash, cash equivalents, and marketable securities will be sufficient to fund its operations for at least the next twelve months.

Negatives

• The company reported a net loss of $13.579 million for Q1 2025, an increase from the $11.664 million loss in Q1 2024.
• Research and development expenses increased, impacting profitability.
• The Phase 4 study comparing YUPELRI to Spiriva HandiHaler did not meet its primary endpoint.

Risks

• The commercial success of YUPELRI depends on its acceptance by physicians, patients, and third-party payors.
• Any delays in clinical studies or adverse results could harm the company's business and stock price.
• The company faces substantial competition from companies with more resources and experience.
• The company depends on single-source manufacturers for its product candidate and YUPELRI.
• The company's strategic review process may not result in an executed or consummated transaction or other strategic alternative.

Future Outlook

The company anticipates top-line data from the ampreloxetine Phase 3 CYPRESS study approximately six months after the final patient is enrolled in late summer 2025 and expects current resources to fund operations for at least the next twelve months.

Industry Context

Theravance Biopharma operates in the competitive biopharmaceutical industry, focusing on respiratory diseases and neurological disorders. The company faces competition from established pharmaceutical companies and generic drug manufacturers. The success of YUPELRI and ampreloxetine depends on factors such as clinical trial outcomes, regulatory approvals, and market acceptance.

Comparison to Industry Standards

• It's difficult to directly compare Theravance Biopharma's Q1 2025 results to industry standards without specific benchmarks for companies of similar size and focus.
• However, the increase in R&D spending is typical for biopharmaceutical companies advancing clinical programs.
• The company's cash position is relatively strong, providing runway for ongoing development activities.
• Competitors in the COPD space include companies like Verona Pharma and Sanofi/Regeneron, while those in the nOH space include generic droxidopa manufacturers.

Legal Proceedings

• The company has settled all litigation with Accord Healthcare, Inc.; Lupin Pharmaceuticals, Inc.; Orbicular Pharmaceutical Technologies Private Limited; Qilu Pharmaceuticals Co., Ltd.; and Teva Pharmaceuticals, Inc. pursuant to individual agreements in which the Company granted these companies a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market their respective generic versions of YUPELRI inhalation solution in the U.S. on or after the licensed launch date of April 23, 2039, subject to certain exceptions as is customary in these type of agreements.
• The patent litigation against the three remaining generic companies, along with certain affiliates, remains pending.
• Further method of treatment patents, with expiration dates of August 2039, were granted on July 30, 2024 and April 29, 2025 and were listed in the Orange Book.
• The Company filed an additional patent infringement suit in the U.S. District Court for the District of New Jersey during August 2024 and May 2025 against the three remaining generic companies.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical development progress directly impact shareholder value.
• Employees: The company's strategic decisions and financial stability affect employee job security and opportunities.
• Patients: The development and commercialization of new medicines like ampreloxetine and YUPELRI impact patient treatment options and quality of life.
• Collaborators: The company's partnerships with Viatris and Royalty Pharma are crucial for the success of its programs.

Next Steps

• Enroll the final patient in the open label period of the ampreloxetine Phase 3 clinical study (CYPRESS) by late summer 2025.
• Await top-line data from the ampreloxetine Phase 3 CYPRESS study approximately six months after the final patient is enrolled.
• Continue to support the commercialization of YUPELRI in collaboration with Viatris.
• Continue to assess all strategic alternatives to the Company, including those related to YUPELRI, ampreloxetine, and TRELEGY.

Key Dates

Keywords

Theravance Biopharma, YUPELRI, Ampreloxetine, Financial Results, Q1 2025, COPD, MSA, Viatris, Royalty Pharma, TRELEGY